Britain’s biggest drugmaker, AstraZeneca, has set out a bold ambition to reach $80bn (£63bn) in revenues by 2030 from treatments for cancer, rare diseases and other conditions, by launching 20 major new medicines before the end of the decade.
As the company presented its growth plans to shareholders at its labs and corporate headquarters in Cambridge, England, its chief executive, Pascal Soriot, said 12 of the 20 new drugs would have the potential to generate more than $5bn in annual revenues at their peak, including five cancer treatments.
